Sage Therapeutics Rejects Biogen’s Acquisition Proposal, Remains Open to Future Deals
Acquisition Proposal:
Sage Therapeutics has rejected a non-binding acquisition proposal from Biogen Inc. but remains open to future deals24.
Strategic Focus:
Sage Therapeutics has outlined its strategic focus for 2025, emphasizing the commercialization of ZURZUVAE for postpartum depression and prioritizing its pipeline in neurodevelopmental disorders and neuropsychiatry12.
ZURZUVAE Growth:
The company aims to establish ZURZUVAE as the first-line therapy and standard of care for postpartum depression, with increased investment in commercialization and disease state awareness efforts to support topline revenue growth in 20251.
Financial Guidance:
Sage Therapeutics anticipates a substantial decrease in R&D and G&A expenses in 2025, with an extended cash runway to mid-20271.
Pipeline Development:
The company is advancing its pipeline, including SAGE-319 for behavioral symptoms associated with neurodevelopmental disorders and SAGE-324 for seizures in developmental and epileptic encephalopathies1.
Sources:
1. https://www.biospace.com/press-releases/sage-therapeutics-to-present-2025-strategic-focus-at-43rd-annual-j-p-morgan-healthcare-conference
2. https://www.tipranks.com/news/company-announcements/sage-therapeutics-outlines-2025-strategy-and-acquisition-proposal